Tandem CD19/CD22 Dual Targets CAR TCells Bridging Hematopoietic Stem Cells Transplantation Acquires Robust Remission for Relapsed and Refractory B Acute Lymphoblastic Leukemia Patients

被引：2
|
作者：
Cui, Wei [1 ]
Zhang, Xinyue [1 ]
Dai, Haiping [1 ]
Cui, Qingya [1 ]
Yin, Jia [1 ]
Li, Zheng [1 ]
Yu, Lei [2 ]
Kang, Liqing [2 ]
Wu, Depei [1 ]
Tang, Xiaowen [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152565
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1753
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
    Phely, Laurent
    Hensen, Luca
    Faul, Christoph
    Ruff, Christer Alexander
    Schneider, Dina
    Bethge, Wolfgang Andreas
    Lengerke, Claudia
    JAMA ONCOLOGY, 2024, 10 (06) : 789 - 792
  • [22] Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
    Jia, Hejin
    Wang, Zhenguang
    Wang, Yao
    Liu, Yang
    Dai, Hanren
    Tong, Chuan
    Guo, Yelei
    Guo, Bo
    Ti, Dongdong
    Han, Xiao
    Yang, Qingming
    Wu, Zhiqiang
    Han, Weidong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [23] Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
    Hejin Jia
    Zhenguang Wang
    Yao Wang
    Yang Liu
    Hanren Dai
    Chuan Tong
    Yelei Guo
    Bo Guo
    Dongdong Ti
    Xiao Han
    Qingming Yang
    Zhiqiang Wu
    Weidong Han
    Journal of Hematology & Oncology, 12
  • [24] CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia
    Maus, Marcela V.
    LANCET, 2021, 398 (10299): : 466 - 467
  • [25] Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
    Tu, Sanfang
    Zhou, Lijuan
    Huang, Rui
    Zhou, Xuan
    Yang, Jilong
    Li, Meifang
    Jin, Bo
    Wang, Langqi
    Zhuo, Yaqi
    Chen, Huifang
    Chang, Lung-Ji
    Li, Yuhua
    BLOOD, 2023, 142
  • [26] CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    Hu, Yongxian
    Zhou, Yali
    Zhang, Mingming
    Ge, Wengang
    Li, Yi
    Yang, Li
    Wei, Guoqing
    Han, Lu
    Wang, Hao
    Yu, Shuhui
    Chen, Yi
    Wang, Yanbin
    He, Xiaohong
    Zhang, Xingwang
    Gao, Ming
    Yang, Jingjing
    Li, Xiuju
    Ren, Jiangtao
    Huang, He
    CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2764 - 2772
  • [27] Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL
    Shalabi, Haneen
    Yates, Bonnie
    Shahani, Shilpa
    Qin, Haiying
    HIghfill, Steven L.
    Panch, Sandhya
    Tran, Minh
    Stroncek, David
    Hoffman, Leah
    Little, Lauren
    Graap, Katherine
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Wang, Hao-Wei
    Fry, Terry J.
    Shah, Nirali N.
    CANCER RESEARCH, 2020, 80 (16)
  • [28] CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas
    Cao, Yang
    Xiao, Yi
    Wang, Na
    Wang, Gaoxiang
    Zhou, Xiaoxi
    Huang, Liang
    Chen, Liting
    Xiao, Min
    Zhang, Tongcun
    Zhang, Yicheng
    Zhou, Jianfeng
    BLOOD, 2020, 136
  • [29] Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/Refractory ALL Patients
    Tang, Xiaowen
    Kang, Liqing
    Qi, Wei
    Cui, Wei
    Dai, Haiping
    Li, Zheng
    Yin, Jia
    Qu, Changju
    Xu, Ting
    Zhu, Xiaming
    Yu, Lei
    Wu, Depei
    BLOOD, 2019, 134
  • [30] Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro
    L Herrera
    RA Farah
    VA Pellegrini
    DB Aquino
    ES Sandler
    GR Buchanan
    ES Vitetta
    Leukemia, 2000, 14 : 853 - 858
12345